X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs WOCKHARDT LTD. - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA WOCKHARDT LTD. DISHMAN PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 25.1 17.2 146.0% View Chart
P/BV x 3.3 1.8 190.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
WOCKHARDT LTD.
Mar-16
DISHMAN PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3742,000 18.7%   
Low Rs129706 18.3%   
Sales per share (Unadj.) Rs197.8403.7 49.0%  
Earnings per share (Unadj.) Rs21.229.5 72.0%  
Cash flow per share (Unadj.) Rs34.742.4 82.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9323.4 55.6%  
Shares outstanding (eoy) m80.69110.51 73.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 38.0%   
Avg P/E ratio x11.945.9 25.8%  
P/CF ratio (eoy) x7.231.9 22.7%  
Price / Book Value ratio x1.44.2 33.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,306149,509 13.6%   
No. of employees `0000.87.4 11.2%   
Total wages/salary Rs m5,3559,443 56.7%   
Avg. sales/employee Rs Th19,252.76,048.6 318.3%   
Avg. wages/employee Rs Th6,459.51,280.2 504.6%   
Avg. net profit/employee Rs Th2,064.1441.5 467.5%   
INCOME DATA
Net Sales Rs m15,96144,614 35.8%  
Other income Rs m265970 27.4%   
Total revenues Rs m16,22645,584 35.6%   
Gross profit Rs m4,1035,038 81.4%  
Depreciation Rs m1,0911,426 76.5%   
Interest Rs m9441,012 93.3%   
Profit before tax Rs m2,3343,570 65.4%   
Minority Interest Rs m0-65 0.0%   
Prior Period Items Rs m16 17.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624255 244.7%   
Profit after tax Rs m1,7113,257 52.5%  
Gross profit margin %25.711.3 227.6%  
Effective tax rate %26.77.1 374.4%   
Net profit margin %10.77.3 146.9%  
BALANCE SHEET DATA
Current assets Rs m11,01839,906 27.6%   
Current liabilities Rs m9,51718,423 51.7%   
Net working cap to sales %9.448.2 19.5%  
Current ratio x1.22.2 53.4%  
Inventory Days Days11090 122.5%  
Debtors Days Days3598 35.5%  
Net fixed assets Rs m16,30435,832 45.5%   
Share capital Rs m161553 29.2%   
"Free" reserves Rs m12,90730,370 42.5%   
Net worth Rs m14,51635,739 40.6%   
Long term debt Rs m4,18916,542 25.3%   
Total assets Rs m29,80579,522 37.5%  
Interest coverage x3.54.5 76.7%   
Debt to equity ratio x0.30.5 62.4%  
Sales to assets ratio x0.50.6 95.4%   
Return on assets %8.95.4 166.0%  
Return on equity %11.89.1 129.4%  
Return on capital %17.58.7 202.6%  
Exports to sales %24.811.6 213.6%   
Imports to sales %3.74.5 83.8%   
Exports (fob) Rs m3,9565,177 76.4%   
Imports (cif) Rs m5961,990 30.0%   
Fx inflow Rs m4,9527,589 65.2%   
Fx outflow Rs m6972,878 24.2%   
Net fx Rs m4,2554,711 90.3%   
CASH FLOW
From Operations Rs m2,786716 389.1%  
From Investments Rs m-1,529-8,182 18.7%  
From Financial Activity Rs m-9412,543 -37.0%  
Net Cashflow Rs m316-4,923 -6.4%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.3 160.9%  
FIIs % 12.7 7.7 164.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 22.1 15.4 143.5%  
Shareholders   46,261 67,757 68.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SHASUN PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS